Aktienanalyse zu Immunome Inc (IMNM)IMNMImmunome Inc

Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Immunome Inc is currently a hold. The stock is priced at $19.55, significantly below the average analyst price target of $34.80, indicating potential upside. However, the RSI is at 27.494, suggesting the stock is oversold, which could lead to a short-term rebound. The main risk is the company's high net losses, with a net income of -$73,127,000 in Q2 2026, which raises concerns about sustainability without revenue growth.